CTOs on the Move

University HealthSystem Consortium

www.uhc.edu

 
UHC, based in Oak Brook, Ill., and representing 0.7 of the academic medical centers in the United States, is an alliance of 84 academic medical centers and 80 associate members.
  • Number of Employees: 1K-5K
  • Annual Revenue: $0-1 Million
  • www.uhc.edu
  • 2001 Spring Rd Ste 700
    Oak Brook, IL USA 60523-1890
  • Phone: 630.954.1700

Executives

Name Title Contact Details

Similar Companies

Cynvenio Biosystems Inc

Cynvenio is a cancer diagnostics company focused on transforming cancer treatment and management through the molecular analysis of cancer biomarkers in blood.

Tanita Corporation of America

Tanita Corporation of America, Inc. is a Arlington Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BrightCoach

BrightCoach is a rapidly growing innovator in the Coaching industry. It is a company of talented, experienced, executive business, and life coaches, dedicated to enriching lives and helping our clients achieve their desired goals. BrightCoach works closely with our clients to help them move forward in a unique one-on-one Coaching relationship to create positive change, leadership skills, active self-discovery and extraordinary results in their lives, careers, businesses or organizations. BrightCoach has developed a unique Coaching methodology combining today’s latest science of change within structured, personalized Coaching programs, to help our clients move from where they are - to where they want to be.

Third Pole

Third Pole, Inc. is a US-based company developing next generation life-saving cardiopulmonary therapies. We are building on our team`s legacy in inhaled nitric oxide (NO), the current standard of care, to develop next generation life-saving heart and lung therapies.

Portola

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.